Advent to sell generic drugmaker Zentiva to GTCR
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
The FDA is beginning rulemaking to close the “adequate provision” loophole
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Maria Soler Nunez appointed as Chief Quality Officer
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Subscribe To Our Newsletter & Stay Updated